FDA Considering “Less Conservative” Approaches To Non-Inferiority Trials
Executive Summary
FDA is considering less conservative approaches to non-inferiority trial designs, Office of Medical Policy Director Robert Temple indicated
You may also be interested in...
Use Of Non-Inferiority Trials Could Increase Despite Unclear Guidance
Regulators need to provide greater clarity on non-inferiority clinical trial designs, an Amgen exec said during FDA's 2006 Science Forum
Use Of Non-Inferiority Trials Could Increase Despite Unclear Guidance
Regulators need to provide greater clarity on non-inferiority clinical trial designs, an Amgen exec said during FDA's 2006 Science Forum
FDA To Consider Critical Path Trial Design Proposals On Case-By-Case Basis
FDA will generally take a case-by-case approach to considering and accepting development programs using clinical trial designs discussed in its Critical Path opportunities list